Table 2.
Results of univariate analysis of risk factors for iDFS and OS in young breast cancer patients.
| Variable | Total (n = 169) | Recurrence/metastasis | χ2 | P | Death | χ2 | P | ||
|---|---|---|---|---|---|---|---|---|---|
| Yes (n = 50) | No (n = 119) | Yes (n = 33) | No (n = 136) | ||||||
| Diagnosis delay | |||||||||
| <6 months | 123 | 33(66.0%) | 90(75.6%) | 1.970 | 0.160 | 19(57.6%) | 104(76.5%) | 3.747 | 0.053 |
| ≥6 months | 46 | 17(34.0%) | 29(22.4%) | 14(42.4%) | 32(23.5%) | ||||
|
| |||||||||
| Menarche | |||||||||
| <14 years | 87 | 29(58.0%) | 58(48.7%) | 0.216 | 0.642 | 17(51.5%) | 70(51.5%) | 0.994 | 0.319 |
| ≥14 years | 82 | 21(42.0%) | 61(51.3%) | 16(48.5%) | 66(48.5%) | ||||
|
| |||||||||
| Pregnancy | |||||||||
| Yes | 43 | 13(26.0%) | 30(25.2%) | 0.265 | 0.607 | 8(24.2%) | 35(25.7%) | 0.170 | 0.680 |
| No | 126 | 37(74.0%) | 89(74.8%) | 25(75.8%) | 101(74.3%) | ||||
|
| |||||||||
| Abortion | |||||||||
| Yes | 33 | 7(14.0%) | 26(21.8%) | 0.425 | 0.514 | 5(15.2%) | 28(20.6%) | 0.103 | 0.748 |
| No | 136 | 43(86.0%) | 93(78.2%) | 28(84.8%) | 108(79.4%) | ||||
|
| |||||||||
| Family history | |||||||||
| Yes | 17 | 46(7.8%) | 106(5.9%) | 0.742 | 0.389 | 3(9.1%) | 14(10.3%) | 0.018 | 0.892 |
| No | 152 | 4(92.2%) | 13(94.1%) | 30(90.9%) | 122(89.7%) | ||||
|
| |||||||||
| PABC | |||||||||
| Yes | 22 | 5(10%) | 17(14.3%) | 0.081 | 0.776 | 5(15.2%) | 17(12.5%) | 0.372 | 0.542 |
| No | 149 | 45(90%) | 102(85.7%) | 28(84.8%) | 121(87.5%) | ||||
|
| |||||||||
| Histological subtypes | |||||||||
| IDL | 148 | 45(90%) | 103(86.6%) | 0.875 | 0.350 | 31(93.9%) | 117(86.0%) | 0.996 | 0.318 |
| Others | 21 | 5(10%) | 16(13.4%) | 2(6.1%) | 19(14.0%) | ||||
|
| |||||||||
| Tumor size | |||||||||
| T1 | 93 | 25(31.1%) | 68(48.5%) | 8.695 | 0.013 | 15(45.5%) | 78(57.4%) | 9.529 | 0.009 |
| T2 | 69 | 22(54.4%) | 47(46.6%) | 15(45.5%) | 54(39.7%) | ||||
| T3 and T4 | 7 | 3(8.7%) | 4(4.4%) | 3(9.1%) | 4(2.9%) | ||||
|
| |||||||||
| Lymph node | |||||||||
| N0 | 92 | 23(30.1%) | 69(57.4%) | 8.287 | 0.04 | 14(42.4%) | 78(57.4%) | 11.732 | 0.008 |
| N1 | 45 | 14(31.1%) | 31(27.9%) | 10(30.3%) | 35(25.7%) | ||||
| N2 | 15 | 4(16.5%) | 11(10.3%) | 2(6.1%) | 13(9.6%) | ||||
| N3 | 17 | 9(22.3%) | 8(4.4%) | 7(21.2%) | 10(7.4%) | ||||
|
| |||||||||
| Lymphovascular invasion | |||||||||
| Yes | 37 | 14(28.0%) | 23(19.3%) | 5.014 | 0.025 | 12(36.4%) | 25(18.4%) | 11.285 | 0.001 |
| No | 132 | 36(72.0%) | 96(80.7%) | 21(63.6%) | 111(81.6%) | ||||
|
| |||||||||
| ER | |||||||||
| Positive | 96 | 22(42.0%) | 74(62.2%) | 5.106 | 0.024 | 14(42.2%) | 82(60.3%) | 3.292 | 0.070 |
| Negative | 73 | 28(56.0%) | 45(37.8%) | 19(57.6%) | 54(39.7%) | ||||
|
| |||||||||
| PR | |||||||||
| Positive | 99 | 21(42.0%) | 78(65.5%) | 8.119 | 0.004 | 13(39.4%) | 86(63.2%) | 5.450 | 0.020 |
| Negative | 70 | 29(58.0%) | 41(34.5%) | 20(60.6%) | 50(36.8%) | ||||
|
| |||||||||
| HER2 | |||||||||
| Positive | 38 | 11(22.0%) | 27(22.7%) | 0.873 | 0.350 | 7(21.2%) | 31(22.8%) | 0.669 | 0.413 |
| Negative | 131 | 39(78.0%) | 92(77.3%) | 26(78.8%) | 105(77.2%) | ||||
|
| |||||||||
| Surgery | |||||||||
| Mastectomy | 72 | 18(36.0%) | 54(45.4%) | 1.775 | 0.183 | 15(45.4%) | 57(41.9%) | 0.136 | 0.712 |
| BCS | 97 | 32(64.0%) | 65(54.6%) | 18(54.5%) | 79(58.1%) | ||||
|
| |||||||||
| SLN/ALND | |||||||||
| SLN | 49 | 10(20%) | 39(32.8%) | 2.552 | 0.110 | 6(18.2%) | 43(31.6%) | 0.450 | 0.502 |
| ALND | 120 | 40(80%) | 80(67.2%) | 27(81.8%) | 93(68.4%) | ||||
|
| |||||||||
| Radiotherapy | |||||||||
| Yes | 129 | 34(68.0%) | 95(79.8%) | 4.491 | 0.034 | 23(69.7%) | 106(77.9%) | 2.387 | 0.122 |
| No | 40 | 16(32.0%) | 24(20.2%) | 10(30.3%) | 30(22.1%) | ||||